Oncolytics Biotech Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CAD 27.75 million compared to CAD 24.84 million a year ago. Basic loss per share from continuing operations was CAD 0.41 compared to CAD 0.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 CAD | +0.62% | +5.88% | -9.50% |
04-11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
04-11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.50% | 88.89M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023